Pain Medications During Pregnancy in PI Cases

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 8 min read

Pregnant personal injury patients face uniquely constrained medication options due to teratogenic risks, fetal toxicity, and labor-related concerns. This guide covers FDA pregnancy categories, safe and contraindicated medications, and the documentation implications for PI cases.

Pain management during pregnancy in personal injury cases requires navigating a restricted pharmacological landscape where many standard PI medications are contraindicated or carry significant fetal risk. Pregnant PI patients cannot receive most NSAIDs in the third trimester, face limited opioid options due to neonatal abstinence syndrome risk, and have virtually no safe benzodiazepine options -- creating a treatment challenge that demands expert pharmaceutical management and thorough documentation.

• Acetaminophen remains the only generally accepted first-line analgesic throughout all trimesters of pregnancy, though recent studies have raised concerns about prolonged high-dose use
• NSAIDs are contraindicated after 20 weeks gestation due to premature ductus arteriosus closure, oligohydramnios, and fetal renal impairment risk, limiting the anti-inflammatory options for pregnant PI patients
• Opioids can be used with caution for moderate to severe pain, but carry neonatal abstinence syndrome (NAS) risk when used near delivery, adding a fetal complication dimension to PI documentation
• Benzodiazepines carry Category D risk (fetal cleft palate, neonatal withdrawal) and are generally avoided, leaving limited pharmacological options for pregnancy-related anxiety after an accident
• The restricted medication landscape for pregnant PI patients documents treatment limitation as a distinct injury consequence

FDA Pregnancy Risk Framework

The FDA replaced the traditional A/B/C/D/X pregnancy category system with the Pregnancy and Lactation Labeling Rule (PLLR) in 2015, requiring narrative risk descriptions rather than letter categories. However, many PI medications still carry the legacy category designations that provide a useful clinical shorthand:

Safe or Relatively Safe Options

Acetaminophen (former Category B): The only analgesic considered generally safe throughout pregnancy. Mechanism: central COX inhibition and endocannabinoid pathway modulation without peripheral prostaglandin inhibition. Maximum dose remains 3-4 grams per day, with liver function monitoring recommended for sustained use. Recent observational studies have suggested associations between prolonged prenatal acetaminophen use and neurodevelopmental effects, but the evidence remains insufficient to change prescribing recommendations.

Certain muscle relaxants: Cyclobenzaprine has limited pregnancy data but no documented teratogenicity. Methocarbamol is similarly limited in data. These are used cautiously when muscle spasm management is essential.

Trimester-Restricted Medications

NSAIDs (former Category B first/second trimester, Category D third trimester): NSAIDs including ibuprofen, naproxen, meloxicam, and diclofenac can be used in the first and second trimesters with caution. However, after 20 weeks gestation, NSAIDs are contraindicated due to:

• Premature ductus arteriosus closure: NSAIDs inhibit prostaglandin E2, which maintains patency of the fetal ductus arteriosus. Premature closure can cause fetal pulmonary hypertension and right heart failure.
• Oligohydramnios: NSAIDs reduce fetal renal prostaglandin production, decreasing fetal urine output and amniotic fluid volume.
• Fetal renal impairment: Prolonged NSAID exposure can damage developing fetal kidneys.

The FDA strengthened this warning in 2020, extending the NSAID contraindication from the traditional "third trimester" (28+ weeks) to 20 weeks gestation for the oligohydramnios risk.

Higher Risk Medications

Opioids (former Category C): Opioids are not teratogenic at standard doses, but carry two significant fetal risks:

• Neonatal abstinence syndrome (NAS): Sustained opioid use near delivery can produce physical dependence in the neonate, with withdrawal symptoms (irritability, high-pitched cry, tremors, feeding difficulties, diarrhea) appearing within 24-72 hours of birth. NAS may require NICU admission and pharmacological treatment (morphine or methadone taper for the neonate).
• Respiratory depression: Opioid administration near delivery can produce neonatal respiratory depression.

Opioids remain an option for moderate to severe injury pain in pregnancy when acetaminophen is insufficient, but require careful timing management relative to delivery and neonatal monitoring planning.

Benzodiazepines (former Category D): Benzodiazepines carry documented risk of fetal cleft palate (first trimester exposure) and neonatal withdrawal syndrome (floppy infant syndrome, respiratory depression, feeding difficulties). They are generally avoided in pregnancy, leaving pregnant PI patients with limited pharmacological options for post-accident anxiety and PTSD.

The Clinical Management Challenge

A pregnant PI patient with cervical strain, lumbar radiculopathy, and post-accident anxiety faces a dramatically constrained medication landscape compared to a non-pregnant patient:

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "The pregnant PI patient represents the most pharmacologically constrained case in personal injury treatment. Every medication decision involves a risk-benefit analysis that includes fetal safety, and the standard PI medication toolkit is reduced to a fraction of its usual scope. This treatment limitation is itself a documentable consequence of the injury."

Documentation Value for PI Cases

The pregnancy-medication intersection creates several distinct documentation opportunities:

Treatment Limitation as Damages

The inability to use standard pain management medications during pregnancy documents that the injury's impact was compounded by the patient's pregnant state. The patient endured undertreated pain because medications that would normally be prescribed were contraindicated. This undertreatment is a real, documentable harm.

Fetal Risk Documentation

When opioids are used during pregnancy for injury-related pain, the neonatal abstinence syndrome risk and any required neonatal monitoring or treatment become additional damages directly attributable to the accident that necessitated pain medication during pregnancy.

Extended Treatment Timeline

Medication restrictions during pregnancy often mean that definitive pharmaceutical treatment (appropriate NSAID therapy, nerve pain medications, adequate sleep medication) must be deferred until after delivery. This extends the treatment timeline by months and documents ongoing injury impact throughout and beyond the pregnancy.

Specialist Involvement

Pregnant PI patients typically require coordination between the treating orthopedist or pain management physician, the obstetrician, and the pharmacist -- a level of care coordination that documents treatment complexity.

LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages. For pregnant PI patients, the MERIT includes specific documentation of pregnancy-related medication restrictions, risk-benefit discussions documented at the pharmacy level, and the clinical rationale for each medication decision in the context of fetal safety.

Lactation Considerations Post-Delivery

After delivery, breastfeeding mothers face continued medication restrictions. Most opioids transfer into breast milk, with codeine carrying particular risk due to variable CYP2D6 metabolism (ultra-rapid metabolizers produce excessive morphine in breast milk). NSAIDs are generally compatible with breastfeeding, but the patient may have deferred NSAID initiation for months and now faces both catch-up pain management and lactation safety considerations.

What PI Attorneys Should Know

Pregnancy does not reduce the severity of a personal injury -- it compounds it by restricting the pharmacological tools available for treatment. The pregnant PI patient's medication record will necessarily show fewer medications, lower doses, and more conservative management than a comparable non-pregnant patient. This apparent simplicity in the medication record should not be misinterpreted as a minor injury. Instead, it documents a treatment limitation that caused the patient to endure undertreated pain, anxiety, and functional impairment due to fetal safety constraints imposed by the accident-related need for medications during pregnancy.